Desk›Healthcare› Wanbury Ltd
Wanbury Ltd
BSE 524212 · NSE WANBURY · ISIN INE107F01022 · Group B · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹254.90
-2.67%
BSE close, 28 August 2026
₹890.61 cr
3.5 cr shares · Micro cap
₹494.19 cr
as published
15.9× · 22.98×
EPS ₹16.00 · BV ₹11.09
650.27 / 66.14
₹ cr, as filed
21
8 selected · 38%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -29.2% |
|---|---|
| Against 52-week low | +57.3% |
| Day change | -2.67% |
| Size band | Micro cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹16.00 |
|---|---|
| Price / earnings | 15.93× |
| Price / book | 22.98× |
| Book value — derived, price ÷ P/B | ₹11.09 |
| Return on equity | 144.24% |
| Operating margin | 10.02% |
| Net margin | 1.96% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 144.26%
- ROE as published
- 144.24%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 165.58 | 3.24 | 0.93 | 10.02% | 1.96% |
| Mar-26 · Q | 164.58 | 21.71 | 7.33 | 16.07% | 13.19% |
| FY25-26 | 650.27 | 66.14 | 20.55 | 16.01% | 10.17% |
Quarter on quarter
- Revenue, quarter on quarter
- +0.6%
- Net profit, quarter on quarter
- -85.1%
- Operating margin, quarter on quarter
- -605 bps
Disclosure profile 21 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Press Release | 4 |
| Change in Management | 2 |
| Board Outcome | 1 |
| Results | 1 |
| Selected sub-total | 8 |
| Procedural | |
| AGM / EGM | 3 |
| General | 2 |
| Newspaper Publication | 2 |
| Annual Report | 1 |
| Board Meeting | 1 |
| Book Closure | 1 |
| Compliance Certificate | 1 |
| ESOP Allotment | 1 |
| Trading Window | 1 |
| Procedural sub-total | 13 |
| Total | 21 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
21 filings · 8 selected · busiest 2026-08-11
Filing rhythm · the twelve most recent
2026-08-132026-10-09
SelectedProcedural
Filings
21 in the window · 14 earlier on record
-
9 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
8 October 2026 ·
Press Release / Media Release
Press Release regarding filing new Drug Master File (DMF) in South Africa for Tramadol HC1 API.
Company Update / Press Release / Media Release View filing →
-
29 September 2026 ·
Closure of Trading Window
Trading Window Closure for the Quarter ended 30th September, 2026.
Insider Trading / SAST / Closure of Trading Window View filing →
-
25 September 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Scrutinizer Report and Voting Results
AGM/EGM / AGM View filing →
-
24 September 2026 ·
-
24 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of the 38th Annual General Meeting of the Company held on Thursday, September 24, 2026 through VC/OAVM
AGM/EGM / AGM View filing →
-
2 September 2026 ·
Newspaper Publication
Newspaper Clipping - Information regarding 38th Annual General Meeting to be held through VC/OAVM.
Company Update / Newspaper Publication View filing →
-
31 August 2026 ·
Notice Of Book Closure For The Purpose Of 38Th Annual General Meeting (AGM).
The register of members and share transfer books of the Company will remain closed from Friday, 18 September, 2026 to Thursday, 24 September, 2026 (both days inclusive) for the purpose ....
Corp. Action / Book Closure View filing →
-
31 August 2026 ·
Reg. 34 (1) Annual Report.
Annual Report 2025-26 and Notice of the 38th Annual General Meeting of Wanbury Limited.
Others / Reg. 34 (1) Annual Report View filing →
-
31 August 2026 ·
Annual Report 2025-26 And Notice Of The 38Th Annual General Meeting Of Wanbury Limited.
Notice of the 38th Annual General Meeting to be held on Thursday, September 24, 2026 at 11:30 A.M. through Video Conferencing( VC)/Other Audio Visual Means (OAVM).
AGM/EGM / AGM View filing →
-
28 August 2026 ·
Newspaper Publication
Newspaper Publication - Information regarding 38th Annual General Meeting to be held on Thursday, September 24, 2026 at 11.30 A.M.
Company Update / Newspaper Publication View filing →
-
13 August 2026 ·
Press Release / Media Release
Press Release regarding EDQM approval for new product Rivaroxaban API, USFDA DMF Clearances.
Company Update / Press Release / Media Release View filing →
-
11 August 2026 ·
Allotment of ESOP / ESPS
Outcome of the Board Meeting held on August 11, 2026
Company Update / Allotment of ESOP / ESPS View filing →
-
11 August 2026 ·
Press Release / Media Release
Press Release on Un-audited Financial Results for the quarter ended 30th June, 2026
Company Update / Press Release / Media Release View filing →
-
11 August 2026 ·
Change in Management
Outcome of the Board Meeting held on August 11, 2026
Company Update / Change in Management View filing →
-
11 August 2026 ·
Financial Results For The First Quarter Ended 30Th June, 2026
Financial Results for the first quarter ended 30th June, 2026
Result / Financial Results View filing →
-
11 August 2026 ·
Board Meeting Outcome for Outcome Of The Board Meeting Held On August 11, 2026
Outcome of the Board Meeting held on August 11, 2026
Board Meeting / Outcome of Board Meeting View filing →
-
3 August 2026 ·
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Wanbury Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve Notice is hereby given pursuant to ....
Board Meeting / Board Meeting View filing →
-
30 July 2026 ·
Press Release / Media Release
Press Release - No DMF deficiency letter received from the office of USFDA for multiple ANDAs
Company Update / Press Release / Media Release View filing →
-
22 July 2026 ·
Intimation Of Completion Of Inspection By The United States Food And Drug Administration (USFDA) At The Company's Facility At Tanuku, West Godavari District, Andhra Pradesh
Intimation of completion of inspection by the United States Food and Drug Administration (USFDA) at the Company's Facilty.
Company Update / General View filing →
-
20 July 2026 ·
Intimation Of Completion Of Inspection By The United States Food And Drug Administration (USFDA) At The Company's Facility At Tanuku, West Godavari District, Andhra Pradesh
A Current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Company's facility at Tanuku, West Godavari District, ....
Company Update / General View filing →
RSS feed for Wanbury Ltd · the 50 most recent filings